EP0402950A2 — Treatment of postmenopausal disorders
Assigned to Orion Oyj · Expires 1990-12-19 · 35y expired
What this patent protects
The present invention relates to a pharmaceutical kit in dosage unit form for use in the treatment of postmenopausal disorders comprising separate dosage units for uninterrupted sequential daily, oral administration, said kit comprised of: (a) 69 separate daily dosage units …
USPTO Abstract
The present invention relates to a pharmaceutical kit in dosage unit form for use in the treatment of postmenopausal disorders comprising separate dosage units for uninterrupted sequential daily, oral administration, said kit comprised of: (a) 69 separate daily dosage units for sequential daily oral ingestion of a naturally occurring or synthetic estrogenic compound effective in the prevention of postmenopausal disorders; (b) 14 separate daily dosage units for sequential daily, oral ingestion of a naturally occurring or synthetic estrogenic compound and a progesterone compound having a progestational activity effective in preventing the development of endometrial hyperplasia; and (c) if desired, 6-8 separate daily dosage units for sequential daily, oral ingestion of a compound free of estrogen and progestogen.
Drugs covered by this patent
- Slynd (DROSPIRENONE) · Exeltis Usa Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.